Jiangsu Hengrui Pharmaceuticals Co.,Ltd (HKG:1276)

Market Cap	425.47B +9.0%
Revenue (ttm)	37.01B +11.6%
Net Income	9.23B +18.7%
EPS	1.39 +11.8%
Shares Out	n/a
PE Ratio	46.10
Forward PE	37.30
Dividend	0.23 (0.39%)
Ex-Dividend Date	Apr 29, 2026

Volume	4,524,616
Open	59.05
Previous Close	58.50
Day's Range	57.70 - 61.75
52-Week Range	51.30 - 95.20
Beta	0.12
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 20, 2026

About HKG:1276

Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. The company develops medicines in the areas of oncology, metabolic and cardiovascular, immunological and respiratory, neuroscience, pain management, infectious, respiratory system, hematological, ophthalmology, and autoimmune and other diseases. The company was founded in 1970 and is headquartered in Lianyungang, China.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1970
• Employees: 20,602
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1276

Financial Performance

In 2025, HKG:1276's revenue was 31.63 billion, an increase of 13.02% compared to the previous year's 27.98 billion. Earnings were 7.71 billion, an increase of 21.69%.

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 10, 2026

Data Sources Report a data error